Phylogica Accesses Novel Half-Life Extension Technology
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Technology Licence to Janssen Biotech
- Share Placement raises $2.15 Million
- Pfizer First Stage of Collaboration Complete
- R&D tax offset refund
- European Patent Granted
Later from PYC Therapeutics
- Phylogica Signs Agreement with MedImmune / AstraZeneca
- R&D Tax Rebate
- Cell-Penetrating Phylomers Improve Delivery of Drugs
- Chief Executive Officer Resignation
- Operational Update
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics